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Abstract
Introduction Total parkinsonian motor symptom severity correlates with presynaptic striatal dopamine function in patients 
with Parkinson’s disease. There is a lack of studies that have investigated the associations between parkinsonian motor 
signs and striatal dopaminergic deficiency in patients with parkinsonism of an unknown origin. Identification of specific 
motor signs associated with the highest likelihood of striatal dopamine deficiency could aid the differential diagnostics of 
parkinsonian and tremor syndromes.
Methods In this cross-sectional clinical and imaging study, detailed motor examinations were performed for 221 patients 
with parkinsonism or tremor of an unknown origin immediately before dopamine transporter (DAT) [I-123]FP-CIT SPECT 
imaging. Region-of-interest and voxel-based methods were used to investigate striatal DAT deficiency in relation to indi-
vidual motor signs.
Results Upper extremity rigidity and facial expression were the only motor signs that differentiated patients with normal 
and abnormal striatal DAT function. The presence of any upper extremity rigidity showed the highest likelihood of DAT 
deficiency (OR 4.79, 95% CI 1.56–14.75, P = 0.006) followed by reduced facial expression (OR 2.14, 95% CI 1.14–4.00, 
P = 0.018). In patients with DAT deficits, reduced facial expression was associated with DAT deficiency specifically in the 
caudate nucleus, and increased upper extremity rigidity was associated with DAT loss in the dorsal putamen (FWE-corrected 
P < 0.05).
Conclusions Increased upper extremity muscle tone and hypomimia are independently associated with a higher likelihood 
of striatal hypodopaminergic imaging finding. This information can be used as a factor when the clinical need of auxiliary 
investigations, such as DAT SPECT, is considered for patients with parkinsonism.
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Introduction
There are numerous neurodegenerative and symptomatic 
causes of parkinsonism [1]. The many causal possibilities 
for parkinsonism are reflected in the suboptimal diagnostic 
accuracy of Parkinson’s disease (PD). A recent meta-anal-
ysis of clinicopathological studies demonstrated that the 
diagnostic accuracy of PD is approximately 75% among 
non-experts [2].
One possible method that could be used to improve 
diagnostic accuracy in parkinsonism of an unknown ori-
gin is presynaptic dopaminergic functional imaging. The 
uptake of putaminal presynaptic dopaminergic tracers 
in positron emission tomography (PET) and single pho-
ton emission computed tomography (SPECT) imaging is 
decreased by approximately 50% in patients with early to 
moderate PD, with practically no overlap when compared 
to healthy individuals [3]. In addition, the differentiation 
of patients with essential tremor (ET) from neurodegen-
erative parkinsonism with dopamine transporter (DAT) 
SPECT imaging has shown a high diagnostic accuracy 
[4]. [I-123]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl)nortropane ([I-123]FP-CIT) SPECT can also 
be used to establish the early diagnosis of neurodegenera-
tive parkinsonism, in the differential diagnosis between 
dementia with Lewy bodies (DLB) and other dementias 
such as Alzheimer’s disease (AD), as well as between neu-
rodegenerative parkinsonism with presynaptic dopamine 
loss (PD, DLB, multiple system atrophy MSA, progressive 
supranuclear palsy PSP and corticobasal syndrome CBS) 
and secondary parkinsonism, e.g., neuroleptic-induced 
parkinsonism [5]. However, its aid in the differentiation 
between vascular parkinsonism (VP) and PD remains 
partly contradictory [6]. Thus, dopaminergic imaging 
appears to represent a useful method for identifying neuro-
degenerative parkinsonism patients with striatal dopamine 
deficits, but the method is costly, has limited availability 
and is associated with radiation. Consequently, the clini-
cal evaluation of parkinsonism patients remains the gold 
standard in most regions of the world.
The current evidence suggests an inverse correlation 
between parkinsonian motor symptom severity, particu-
larly of bradykinesia and axial symptoms, and striatal DAT 
binding in patients with PD [7], whereas rigidity appears 
to correlate moderately and tremor only very weakly, 
or not at all, with striatal DAT binding [7, 8]. It should 
be noted, however, that a large proportion of the previ-
ous data has been collected in research studies that have 
investigated patients with established diagnoses of PD 
and healthy individuals, and thus, the results may con-
vert poorly to a clinical setting when patients present with 
unclear or atypical parkinsonian motor symptoms. There 
is a lack of studies that have investigated the associations 
of individual parkinsonian motor signs with striatal dopa-
mine deficiency in patients with clinical parkinsonism and 
tremor of an uncertain origin.
A widely used method in quantitative phenotyping of PD 
is the Unified Parkinson’s Disease Rating Scale (UPDRS), 
which revision, MDS-UPDRS was published in 2008 [9]. 
In the present study, we used functional DAT imaging and 
MDS-UPDRS motor scoring for 221 patients with parkin-
sonism or tremor of an unknown origin. The aims of the 
study were to identify parkinsonian motor signs that point to 
striatal dopaminergic deficiency, and to investigate whether 
these associations are particularly present in certain striatal 
subregions in patients with striatal DAT deficits.
Patients and methods
Patients and study description
This cross-sectional clinical and imaging study consisted 
of patients scanned with [I-123]FP-CIT SPECT because of 
parkinsonism or tremor of an unknown origin. The imag-
ing was performed between the years of 2014–2017 at two 
centers. All patients were clinically examined 2–4 h before 
scanning. The examinations included a clinical interview, 
part III of the MDS-UPDRS [9], the original Hoehn and 
Yahr (H&Y) stage [10, 11] and the Mini-Mental State 
Examination (MMSE) [12]. Two-hundred and twenty-one 
consecutive patients willing to participate in the study and 
who were examined before February 2017 with complete 
MDS-UPDRS-III ratings and successful semi-quantitative 
scan analyses were included in the analyses. One-hundred 
and seventy-eight patients (80.5%) were scanned and exam-
ined in Center 1 and 43 (19.5%) in Center 2. Forty (18.1%) 
patients were receiving antiparkinsonian medications at the 
time of clinical examination and imaging. The study was 
approved by the Ethics Committees of the Hospital Districts, 
and was conducted according to the principles of the Decla-
ration of Helsinki. Informed consent was obtained from all 
participants included in the study.
To investigate individual parkinsonian motor features, 
the MDS-UPDRS part III ratings were divided into six 
main subscores: bradykinesia, rigidity, tremor, axial signs, 
speech and facial expression, modified from the subscores 
from the original motor UPDRS ratings [7]. The toe tap-
ping and freezing of gait items, which were not included in 
the original UPDRS [9], were included in the bradykinesia 
and axial signs subscores, respectively. Tremor was further 
categorized into rest, postural and kinetic tremors, and the 
asymmetry indices were calculated for the lateralized signs 
(Supplementary Table).
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SPECT imaging and image analyses
The SPECT imaging procedure and the image analyses, 
including the region-of-interest (ROI) analysis (BRASS, 
version 2.6H. by Hermes Medical solutions, Stockholm, 
Sweden) with scanner-specific corrections and patient age 
corrections for the specific binding ratio (SBR) calculations 
of six striatal ROIs (Supplementary Table 1), and the voxel-
based image analysis (SPM12, http://www.fil.ion.ucl.ac.uk/
spm/softw are/spm12 /), are described in detail in the Sup-
plementary Material.
The original interpretations of the scans by nuclear 
medicine physicians were reviewed, but the classifica-
tion of patients into the normal and abnormal DAT bind-
ing groups was based on the automated semi-quantitative 
BRASS analysis. A scan was defined as abnormal if the 
semi-quantitative uptake was more than two standard devia-
tions below the reference mean in any of the six analyzed 
regions [13]. Cases on the borderline of abnormality (n = 11) 
in the original evaluations were carefully re-evaluated, and 
a consensus decision was made by the investigators, based 
both on the visual interpretations and the initial and new 
semi-quantitative analyses with both age and camera correc-
tions for the striatal SBRs [13], as described [14].
Statistical analyses
The assumption of normality was evaluated visually from 
histograms together with Shapiro–Wilk tests. Mann–Whit-
ney U tests and Chi-square tests were used to investigate 
group differences in the continuous and categorical vari-
ables, respectively. The Benjamini–Hochberg procedure 
was applied to control the probability of type I errors due 
to multiple comparisons of all the motor signs, with a false 
discovery rate of 5%. Binary logistic regression analyses 
were used to study whether the demographical and clinical 
factors that significantly differed between patients with and 
without striatal DAT deficiency had a higher likelihood of 
abnormal DAT binding. ORs for the motor signs were cal-
culated for the presence of signs vs. no signs due to clinical 
interest. ROC curves for continuous upper extremity rigid-
ity total score and facial expression score were plotted and 
areas under the curves (AUCs) were analyzed. Cut-off values 
were calculated for these variables, and for motor symptom 
duration from the corresponding ROC analyses by applying 
and choosing the maximum value of the Youden’s index 
[15]. One-way ANOVA was used to investigate differences 
in putamen and caudate DAT binding with respect to facial 
expression (0–4 points on the MDS-UPDRS) and mean 
upper extremity rigidity scores (0–0.5, 1–1.5, 2–2.5, 3–3.5, 
and 4 points), and to investigate differences in DAT bind-
ing between the SPECT scanners. Patients with the highest 
facial expression scores (3 and 4) and mean upper extremity 
rigidity scores (3–3.5 and 4) were combined because of the 
low number of patients with a score of 4. The equality of 
variances was tested with Levene’s test. Tukey HSD correc-
tions were used to correct for multiple comparisons in the 
ANOVAs. P values less than 0.05 were considered signifi-
cant. For all analyses, IBM SPSS Statistics Version 24 (IBM 
Corp., New York, USA) was used.
Finally, we investigated the striatal subregions where the 
motor signs showed associations with the imaging outcome 
(facial expression and upper extremity rigidity) stemmed 
from using the voxel-wise approach in SPM12. The analyses 
were restricted to the patients with abnormal DAT bind-
ing. One patient lacked the imaging data and was therefore 
left out of these analyses. The effect of hypomimia (scores 
of 2–4 vs. 0–1, n = 50 vs. n = 59) or mean upper extrem-
ity rigidity (scores of 2–4 vs. 0–1.5, n = 56 vs. n = 54) was 
investigated using univariate regression models and a mul-
tivariate regression model. A stringent statistical threshold 
was used, considering only voxel-level family wise error 
(FWE)-corrected P values less than 0.05 to be significant. 
The cluster coordinates are presented for all clusters with 
spatial extents of more than 5 voxels. All of the analyses 
were also conducted in the subsample of patients who were 
not receiving antiparkinsonian medications at the time of 
imaging and clinical examinations.
Results
Differences between patients with normal 
and abnormal striatal DAT binding
There were 110 patients with abnormal DAT binding and 
111 patients with normal DAT binding. Patients with normal 
and abnormal DAT binding did not differ in terms of age, 
sex, education level, general cognitive capacity (MMSE), 
MDS-UPDRS total score (Fig. 1a) or H&Y stage (Fig. 1b) 
(Table 1). Patients with normal DAT binding had longer 
motor symptom durations than patients with abnormal bind-
ing (Table 1). When analyzing MDS-UPDRS-III subscores, 
speech, bradykinesia total score, axial signs, tremor total 
score (Table 1), and any tremor category (Supplementary 
Table 2) did not differ between patients with normal and 
abnormal DAT binding.
Patients with abnormal DAT binding had greater rigidity 
(total score) than patients with normal binding (Table 1). The 
difference in rigidity was significant in the upper extremities 
(48.8% higher mean upper extremity rigidity total scores 
in abnormal patients, Table 1; Fig. 1c) but not in the lower 
extremities or neck (Table 1). Patients with abnormal DAT 
binding scored higher also in terms of facial expression than 
patients with normal binding (Table 1; Fig. 1d). Asymmetry 
indices of motor signs, especially the asymmetry indices of 
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rigidity and bradykinesia items, were higher in patients with 
abnormal DAT binding (Supplementary Table 2), but these 
results did not remain significant after the Benjamini–Hoch-
berg procedure.
Associations of rigidity and facial expression 
with DAT binding
The presence of any upper extremity rigidity (scores of 1–4 
vs. 0 in at least one upper extremity) and the presence of any 
loss in facial expression (scores of 1–4 vs. 0 on the facial 
expression item) were associated with a higher likelihood 
of striatal DAT deficiency (Table 2). Each 1-year increase 
in the motor symptom duration was associated with a lower 
likelihood of DAT deficiency (Table 2). Upper extremity 
rigidity, hypomimia and motor symptom duration were all 
independently associated with abnormal or normal striatal 
DAT binding when included in the multivariate regression 
model (Table 2). The cut-off values were 2.5 points for upper 
extremity rigidity total score, 1.5 for facial expression score, 
Fig. 1  Group differences (a–d) and the effects of hypomimia and 
increasing upper extremity rigidity in patients with striatal DAT defi-
cits (e, f). a, b There were no differences in the overall motor symp-
tom severity between patients with normal and abnormal striatal DAT 
binding. c, d Upper extremity rigidity and facial expression were 
the only motor signs that differed between patients with and without 
striatal DAT deficits. Box plots and whiskers represent the medians 
and the 25–75 and 5–95 percentiles, respectively, and the means 
are shown as ‘+’. e, f In patients with striatal DAT deficits, reduced 
facial expressions were particularly associated with the reduced cau-
date nucleus DAT binding. e F = 7.51, P < 0.001. 0 vs. 1, P = 0.029; 
0 vs. 2, P = 0.001; 0 vs. 3–4, P < 0.001; 1 vs. 3–4, P = 0.068; 1 vs. 
2, P = 0.64; 2 vs. 3, P = 0.33. f F = 3.88, P = 0.011. 1–1.5 vs. 3–4, 
P = 0.006; 2-2.5 vs. 3–4, P = 0.12; rest pairwise post hoc compari-
sons, P > 0.43. Means are shown as lines. ***P < 0.001, **P < 0.01, 
*P < 0.05, NS non-significant
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and 1.58 years for motor symptom duration, and the AUCs 
for upper extremity rigidity were 0.68 (95% CI 0.61–0.75), 
P < 0.001 and 0.61 (95% CI 0.53–0.68), P = 0.006 for facial 
expression (Supplementary Figure).
In patients with DAT deficiency, caudate DAT bind-
ing was associated with facial expression scores (F = 7.51, 
P < 0.001, Fig. 1e). Putamen DAT binding was associ-
ated with facial expression (F = 4.52, P = 0.005) but with 
only one significant pairwise post hoc comparison (0 vs. 
3, P = 0.005, 1 vs. 3, P = 0.054, 0 vs. 2, P = 0.060; the 
rest comparisons, P > 0.32). Upper extremity rigidity was 
associated with caudate (F = 3.88, P = 0.011, Fig. 1f) and 
putamen DAT binding (F = 3.17, P = 0.027, one significant 
pairwise post hoc comparison of 1–1.5 vs. 3–4, P = 0.024; 
the rest comparisons, P > 0.27). In patients with normal 
DAT binding, no associations were observed between 
facial expression and caudate (F = 1.21, P = 0.31) or puta-
men DAT binding (F = 1.24, P = 0.30) or between upper 
extremity rigidity and caudate (F = 1.08, P = 0.36) or puta-
men DAT binding (F = 1.49, P = 0.22).
In the voxel wise analyses, reduced facial expression 
was associated with reduced DAT binding bilaterally in the 
caudate nucleus (cluster 1 extent 459 voxels, peak at − 14 
− 3 24 with Tmax = 4.51, PFWE = 0.003; cluster 2 extent 
456 voxels, peak at 9 20 0 with Tmax = 4.31, PFWE = 0.006) 
(Fig. 2a). Upper extremity rigidity was associated with 
lower DAT binding in the left putamen (cluster extent 74 
voxels, peak at − 22 − 8 12 with Tmax = 4.24, PFWE = 0.007) 
(Fig. 2b). When using multivariate regression that included 
both signs in the model, both the hypomimia (cluster 1 
Table 1  Demographic and 
clinical characteristics, together 
with the motor examination 
results of 221 patients with 
parkinsonism or tremor of 
an unknown origin with and 
without striatal dopamine 
transporter (DAT) binding 
deficiency in [I-123]FP-CIT 
SPECT imaging
Mann–Whitney U tests were used to investigate continuous variables and Chi-square tests were used to 
investigate categorical variables. Values are presented as n or mean (SD) for demonstrative purposes. Num-
bers of missing values: education n = 3, MMSE n = 2, motor symptom duration n = 22, facial expression 
n = 1, axial symptoms n = 10, bradykinesia total score n = 3
MMSE Mini-Mental State Examination
*Significant after multiple comparisons correction using Benjamini–Hochberg procedure
Italic values indicate significance of P value (P < 0.05)
DAT normal (n = 111) DAT abnormal 
(n = 110)
P value
Demographic and clinical characteristics
Age (years) 64.2 (12.2) 65.5 (9.4) 0.88
Sex (F/M) 54/57 55/55 0.84
Formal education (years) 12.6 (4.7) 13.2 (4.1) 0.19
MMSE score 26.2 (3.1) 26.6 (2.7) 0.27
Motor symptom duration at scan (years) 4.3 (5.8) 2.6 (3.7) 0.013
Motor examination
Original Hoehn and Yahr stage 2.2 (0.9) 2.1 (0.9) 0.42
MDS-UPDRS part III total score 37.0 (17.4) 40.2 (15.9) 0.13
Facial expression 1.03 (0.89) 1.39 (0.92) 0.004*
Speech 0.81 (0.84) 0.96 (0.91) 0.22
Axial signs 4.19 (3.51) 4.46 (3.83) 0.70
Bradykinesia total score 16.60 (9.04) 18.10 (9.24) 0.27
Tremor total score 6.84 (5.28) 6.15 (4.39) 0.48
Rigidity total score 7.02 (4.53) 8.88 (4.62) 0.002*
Neck rigidity 1.44 (1.36) 1.75 (1.40) 0.09
Lower extremity rigidity total score 3.14 (2.36) 3.50 (2.42) 0.27
Upper extremity rigidity total score 2.44 (1.81) 3.63 (1.79) < 0.001*
Table 2  Logistic regression 
analyses of the motor signs 
and motor symptom duration 
that differed between patients 
with and without striatal DAT 
deficiency in [I-123]FP-CIT 
SPECT
Univariate analyses Multivariate model
OR P value 95% CI OR P value 95% CI
Hypomimia 2.14 0.018 1.14–4.00 2.15 0.025 1.10–4.20
Upper extremity rigidity 4.79 0.006 1.56–14.75 3.34 0.045 1.03–10.86
Motor symptom duration (years) 0.92 0.023 0.86–0.99 0.92 0.026 0.86–0.99
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extent 234 voxels, peak at − 14 − 3 24 with Tmax = 4.26, 
PFWE = 0.007; cluster 2 extent 262 voxels, peak at 10 20 
0 with Tmax = 3.93, PFWE = 0.01) and the upper extremity 
rigidity (cluster extent 53 voxels, peak at − 26 − 8 − 12 
with Tmax = 4.10, PFWE = 0.01) effects remained significant.
All of the previous results, except the association between 
hypomimia and a higher likelihood of DAT deficiency, 
remained the same in the subsample of patients without 
antiparkinsonian medications (Supplementary Material). 
The results remained essentially the same when patients on 
SSRI/SNRI medications were excluded from the analyses.
Discussion
The present results indicate that the presence of upper 
extremity rigidity and reduced facial expression are indepen-
dently associated with a higher likelihood of striatal dopa-
mine deficiency in patients with parkinsonism or tremor of 
an unknown origin. On the other hand, overall motor symp-
tom severity or other common parkinsonian motor signs, 
such as bradykinesia or rest tremor, did not differ between 
parkinsonism patients with normal and abnormal DAT bind-
ing. Furthermore, parkinsonian hypomimia appears to be 
associated with dopamine degeneration particularly in the 
caudate nucleus. It should be noted that a longer duration 
of motor symptoms was associated with a lower likelihood 
of DAT deficiency. Thus, this result confirms our previous 
findings, probably reflecting the less progressive nature of 
parkinsonian symptoms in patients with normal DAT bind-
ing [16].
The highest likelihood of DAT deficiency was observed 
with upper extremity rigidity in at least one body side. The 
OR was even higher in the subsample of patients who were 
not receiving antiparkinsonian medications. We are not 
aware of any previous studies that have investigated the asso-
ciation of upper extremity rigidity and DAT deficiency. The 
reason why in particular upper extremity rigidity was indica-
tive of DAT loss might be due to many factors that cause and 
mimic increased lower extremity muscle tone and problems 
with gait, such as lumbar spine degenerative changes and 
degenerative arthritis, resulting in apparent lack of differ-
ences in the lower extremity rigidity scores between groups. 
It is of special interest that, unlike most other items on the 
motor MDS-UPDRS, the estimation of rigidity is not based 
on inspection but rather requires hands-on examination by 
the clinician. However, in accordance with earlier results of 
correlations between DAT and rigidity [7], there were only 
mild associations between the magnitude of DAT binding 
and the severity of upper extremity rigidity. This may have 
been partially due to inter-rater variability in the rigidity 
severity estimates. Thus, the detection of upper extremity 
rigidity might serve as a clinical trigger-finding (yes/no) for 
neurodegenerative parkinsonism disorders associated with 
dopamine loss even if it cannot be used as a reflector of the 
magnitude of striatal dopamine deficiency.
Fig. 2  Associations between 
reduced striatal DAT binding 
and hypomimia (a) and upper 
extremity rigidity (b). Statistical 
t maps including only voxels 
with voxel-level FWE-corrected 
P < 0.05 are shown and overlaid 
on the MNI152 T1-weighted 
template
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A reduction in facial expression, as seen in reduced eye-
blink frequency, masked faces, reduced spontaneous smiling 
and parting of the lips, was also associated with a higher 
likelihood of DAT deficiency. Hypomimia, the reduction of 
spontaneous facial movements and emotional facial expres-
sions, is a common feature of neurodegenerative parkin-
sonism. Previous results have indicated that reduced facial 
expression in PD could be a reflection of facial bradykin-
esia that differs from bradykinesia in the limbs, as facial 
movements are not only voluntary but also involuntary 
(spontaneous and emotional) [17]. The loss of spontaneous 
facial expression, such as a reduced blinking rate, has been 
suggested to be related to central dopamine deficiency and 
to respond well to dopaminergic medication [18]. On the 
other hand, the impairment in emotional facial expressive-
ness seems to correlate with the impairment of facial emo-
tions recognition both in PD [19] and in healthy individu-
als [20]. It should be noted that, as the association between 
hypomimia and a higher likelihood of DAT deficiency was 
not observed in the subsample analyses, there was a pos-
sible medication effect in hypomimia. However, the present 
results, also the subsample analyses, further pointed to a 
specific association between the decreased facial expression 
and the reduced dopamine function in the caudate nucleus in 
patients with abnormal DAT binding. It is of special interest 
to note that apathy, a common neuropsychiatric symptom 
in PD, has also been reported to be associated with caudate 
DAT function in early PD [21]. Given the difficulties in emo-
tional processing of PD patients at multiple levels [22], the 
impairment in emotional facial expressiveness [19], and the 
localization of hypomimia in the caudate nucleus and not 
in the nigrostriatally more relevant putamen, we consider 
that apathy and hypomimia could represent different but 
interconnected aspects of abnormal emotional functions in 
neurodegenerative parkinsonism. Further studies are needed 
to investigate whether the relationship between facial expres-
sion and dopamine is driven more by motor circuitry or by 
emotional processing.
It is noteworthy that the degree of bradykinesia, the 
most cardinal feature of parkinsonism and PD [23], did not 
distinguish parkinsonism patients with normal and abnor-
mal DAT uptake. Thus, the spectrum of neurodegenerative 
and non-neurodegenerative causes of bradykinesia may 
clinically appear as similar levels of bradykinesia. Slow-
ness of movements is part of the motor dysfunction in 
many movement disorders, it can be present in any condi-
tion with muscle weakness, and it may also be included in 
the phenotype of depression [24]. The present results can-
not be interpreted to lessen the value of bradykinesia in the 
diagnostics of PD nor the important role of the slowness 
of movements in the pathophysiology of parkinsonism. 
Our finding rather noted the difficulties when one tries to 
identify patients with dopaminergic degeneration on the 
basis of bradykinesia. Indeed, the terminology considering 
bradykinesia and its different dimensions has been highly 
variable in the earlier literature [25], and it has been spec-
ulated that the different dimensions of bradykinesia should 
be rated separately [23]. A previous blinded video study 
demonstrated that the clinical symptom-based separation 
of tremulous patients with and without dopamine defi-
ciency is difficult even for movement disorder specialists, 
and it was also noted that the true parkinsonian bradyki-
nesia with both slowness and decrement is very hard to 
diagnose [26]. In line with that study, our study under-
lines the similarities in tremor signs in a large number of 
patients by showing that the presence or the magnitude 
of rest, postural or kinetic tremors has minimal value in 
predicting striatal dopamine loss in a heterogeneous clini-
cal sample of parkinsonism patients. Not even the tremor 
asymmetry index was able to differentiate between the two 
patient groups with and without DAT deficiency in the pre-
sent study. However, it is noteworthy that the asymmetry 
of all bilateral motor signs, bradykinesia items and rigidity 
tended to be more pronounced in patients with abnormal 
DAT binding, and this finding needs more detailed inves-
tigation in the future studies.
The important strengths of the study were the unbiased 
motor evaluations (not biased by the knowledge of the 
imaging results) and automated semi-quantitative age- and 
scanner-corrected ROI analyses, along with voxel-by-voxel 
analyses. In addition, the scans with semi-quantitative analy-
ses on the borderline of abnormality underwent a separate 
visual expert evaluation when these scans were categorized 
into groups of normal and abnormal DAT binding [27]. The 
distribution of patients with normal and abnormal DAT 
binding were similar to the earlier retrospective results of 
patients scanned in Center 1 [28]. Regarding limitations, the 
study sample consisted of patients who were scanned with 
SPECT due to clinical diagnostic difficulties, and therefore, 
the sample was probably not fully representative of typi-
cal parkinsonism patients in neurological outpatient clinics. 
Nevertheless, the sample represents clinical neurological 
diagnostic reality much better than studies where com-
parisons were made between patients with established PD 
diagnoses and healthy controls. The MDS-UPDRS part III 
scores were somewhat higher when compared to some previ-
ous studies of PD patients [9], but this can be explained by 
the study setting and study sample that included also more 
advanced parkinsonism patients with also other diagnoses 
than PD. As a limitation, it should be noted that the MDS-
UPDRS rating scale was developed for PD patients in par-
ticular and it may not be as suitable for other patient groups. 
The present results were limited also because they focused 
on motor function and were derived from motor examina-
tions only, without possibly relevant non-motor predictive 
signs of striatal DAT loss. Finally, cerebrovascular disease 
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could affect both DAT SPECT imaging and motor symp-
toms if there are ischemic lesions in relevant regions along 
the nigrostriatal tract. However, from hospital records we 
identified only two patients who had striatal DAT deficiency 
with parallel evidence of possibly relevant vascular lesions.
Conclusions
The present study demonstrates that the presence of upper 
extremity rigidity and reduced facial expression, when 
assessed using the clinimetric properties of the motor MDS-
UPDRS, are associated with a higher likelihood of striatal 
dopamine neurotransmission deficiency in patients with 
parkinsonism or tremor of an unknown origin. Reduced 
facial expression appears to be specifically associated with 
decreased caudate nucleus dopamine function. This could 
bear relevance not only for motor facial dysfunction, but 
also for possible pathophysiological emotional mechanisms 
of hypomimia in neurodegenerative parkinsonism.
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